Medpace Holdings, Inc. (MEDP) is a publicly traded company in the Healthcare — Medical - Diagnostics & Research industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance.
Is Medpace Holdings, Inc. stock overvalued or undervalued in 2026?
Medpace Holdings, Inc. (MEDP) trades at 36.1× earnings (P/E), above the median of the 246 healthcare companies over $2bn in Kaplio's universe. At the decade median (37.5×) $676 (+4 %); at its sector median (30.4×) $549 (-16 %).
Kaplio overview: Medpace Holdings, Inc.
Market cap $18B · 52 weeks $393 – $693 (6 % below the high) · P/E 36.1× · 2027 expected P/E 33.1× · Dividend none · Next earnings February 8, 2027 · expected EPS $4.82 · Closing price, Oct 30 · accounts published Oct 21.
- Valuation: P/E 36.1× (fairly priced).
- Business: ROIC 62 % (excellent).
- Balance sheet: Net cash/EBITDA 0.4× (solid).
- Earnings: 8 of 8 (on track).
What would it be worth at its usual multiples?
At the decade median (37.5×) $676 (+4 %); at its sector median (30.4×) $549 (-16 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 5 of 7 pass
- R&D / Revenue 0.0 %, fails.
- Gross margin 30.1 %, fails.
- 5y EPS growth 30.8 %, passes.
- FCF / Net Income 151.1 %, passes.
- ROIC 62.2 %, passes.
- Net debt / EBITDA −0.4×, passes.
- P/E vs own 10y history 36.1×, passes.
Against its peers (reference peers) — Medpace Holdings, Inc.: P/E 36.1×; EV/EBITDA 27.5×; ROIC 62.2 %; $18.2B. Charles River Laboratories International, Inc. (P/E —; EV/EBITDA 91.4×; ROIC 7.7 %; $17.3B), ICON Public Limited Company (P/E 36.4×; EV/EBITDA 13.9×; ROIC 4.8 %; $16.3B), IQVIA Holdings Inc. (P/E 32.5×; EV/EBITDA 16.2×; ROIC 8.2 %; $44.1B).
Expensive or cheap against its last 8 years?
P/E at each close: today 36.1× · median 37.5× · minimum 22.0× · maximum 60.1× · cheap below 32.5× · expensive above 43.9×. It has been cheaper than today only 43% of the time over its last 8 years.
Profitability
| Return on Equity | 99.76% |
| Return on Invested Capital | 62.17% |
| Return on Assets | 22.49% |
| Gross Margin | 29.14% |
| Operating Margin | 21.39% |
| Net Margin | 18.24% |
Financial Health
| Debt / Equity | 0.25 |
| Current Ratio | 0.83 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 8.04 |
Price Performance
| 1 month | +8.76% |
| 3 months | +13.73% |
| Year-to-date | +16.09% |
| 1 year | +11.47% |
| 3 years | +146.38% |
| 5 years | +187.44% |
| 10 years | +2142.90% |
Related companies: ICLR · FTRE · IQV · CRL
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of MEDP: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks